8-K: Supernus Pharmaceuticals to Announce Q4 and Full Year 2023 Results on February 27th

Supernus Pharmaceuticals will release its fourth quarter and full year 2023 financial results after market close on February 27, 2024, followed by a conference call.

Summary

• Supernus Pharmaceuticals, a biopharmaceutical company focused on central nervous system (CNS) treatments, will announce its financial results for the fourth quarter and full year 2023 on February 27, 2024.
• The announcement will be made after the market closes.
• A conference call and webcast will be held on the same day at 4:30 p.m. ET to discuss the results.
• The call will include prepared remarks from management, a discussion of business results, and a question-and-answer session.
• A live webcast and a replay will be available on the company's investor relations website.

Sentiment

Score: 7

Explanation: The document is a routine announcement of an upcoming earnings release, which is generally neutral to positive. The company is providing clear communication to investors.

Positives

• The company is providing a clear date and time for the release of its financial results.
• A conference call and webcast will be available for investors to discuss the results with management.
• The webcast will be available for an extended period of 60 days.

Risks

• The announcement of financial results could lead to volatility in the company's stock price.
• The company's performance may not meet investor expectations.

Future Outlook

The company will be discussing its fourth quarter and full year 2023 financial and business results on the conference call.

Management Comments

• Jack Khattar, President and CEO, and Tim Dec, Senior Vice President and CFO, will host the conference call.

Industry Context

This announcement is a standard practice for publicly traded companies to inform investors about their financial performance, and is typical for a biopharmaceutical company.

Comparison to Industry Standards

• The timing of the earnings release and conference call is consistent with industry practices for publicly traded pharmaceutical companies.
• Many similar companies such as Biogen, Vertex Pharmaceuticals, and Regeneron also release quarterly and annual results and host conference calls with investors.

Stakeholder Impact

• Shareholders will be informed about the company's financial performance.
• Investors will have the opportunity to ask questions during the conference call.
• The company's performance will impact investor confidence.

Next Steps

• The company will release its Q4 and full year 2023 financial results after market close on February 27, 2024.
• A conference call and webcast will be held on February 27, 2024 at 4:30 p.m. ET.

Key Dates

Keywords

Supernus Pharmaceuticals, Financial Results, Q4 2023, Full Year 2023, Conference Call, Webcast, CNS, Biopharmaceutical